SOPHiA GENETICS SA (SOPH) 株式分析

企業概要

SOPHiA GENETICS SA operates as a cloud-native software technology enterprise within the healthcare ecosystem, providing the SOPHiA DDM platform which facilitates the analysis of multimodal data sets and the generation of diagnostic insights. The company functions specifically within the Healthcare sector, with a specialized focus on the Health Information Services industry, positioning itself as a provider of advanced data analytics solutions for diagnostic modalities. As of the latest reporting period, the company demonstrates a market capitalization of $348.31M, generates annual revenue of $77.27M, and employs a workforce of 415 individuals. These financial and operational metrics indicate that while the enterprise maintains a substantial operational footprint with a significant employee base, its market valuation reflects a smaller-cap status relative to large-cap peers, suggesting a mid-stage growth trajectory typical for specialized health information service providers.

財務健全性

The company reported revenue of $77.27M over the trailing twelve months, yet it recorded a net income of $-78,999,000 and an EBITDA of $-69,168,000, revealing a significant structural gap where operating expenses substantially exceed gross profit generation. This negative profitability indicates that the cost structure is currently driven by high operational expenditures, likely associated with research and development or scaling cloud infrastructure, which outweighs the revenue generated at the current scale. The free cash flow stands at $-16,462,000, which signifies that the company is burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility for capital expenditures or aggressive expansion without external financing. In terms of profitability efficiency, the gross margin is 67.4%, indicating strong pricing power or cost control on the cost of goods sold, while the operating margin is -85.4% and the profit margin is -102.2%, showing that overhead costs are consuming the majority of revenue before reaching the bottom line. The balance sheet shows cash holdings of $70.29M against total debt of $63.02M, resulting in a debt-to-equity ratio of 133.67, which suggests a highly leveraged position where equity is significantly lower than total debt obligations. Despite the high leverage, the current ratio is 1.96, indicating that the company holds sufficient current assets to cover its short-term liabilities with nearly double the liquidity required, providing a buffer against immediate solvency pressures. Furthermore, the return on equity is -110.0% and the return on assets is -27.9%, metrics that reveal that management is currently destroying value relative to the shareholders' equity and the total asset base utilized to generate operations.

バリュエーション評価

The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is reported at -8.68, implying that the market anticipates continued negative earnings in the near term or requires a specific timeframe to achieve positive earnings normalization. The price-to-book ratio stands at 7.06, indicating that the market is valuing the company at a significant premium over its tangible book value, which often occurs in technology firms where intangible assets and intellectual property are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 4.51 and an EV/EBITDA of -4.93 suggest that investors are pricing the stock based on revenue potential and future growth expectations rather than current earnings power. The stock price has fluctuated within a range defined by a 52-week high of $5.70 and a 52-week low of $2.58, meaning the current trading position must be contextualized within this volatility band to assess relative entry or exit points. Additionally, the beta value is 1.04, which indicates that the stock's price volatility is slightly higher than the broader market benchmark, suggesting that price movements will likely outpace or outpace the market index during periods of significant market swings.

Growth & Income

The company is experiencing robust revenue expansion with a year-over-year revenue growth rate of 22.4%, whereas earnings growth is listed as N/A due to the company's current loss-making status, highlighting a divergence where top-line growth is occurring while profitability remains elusive. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders but instead retains all earnings to fund operations and growth initiatives. This strategic choice to forgo dividends aligns with the company's need to reinvest capital into its cloud-native platform development and market penetration rather than returning value via cash distributions. The overall growth and income profile is characterized by high revenue momentum coupled with a complete absence of dividend income, reflecting a high-risk, high-reward equity structure typical of early-stage biotech or health-tech software firms that prioritize expansion over shareholder returns.